BioCardia Inc (BCDA)
2.40
+0.01
(+0.42%)
USD |
NASDAQ |
Nov 04, 13:15
BioCardia Net Income (Quarterly): -1.646M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -1.646M |
| March 31, 2024 | -2.267M |
| December 31, 2023 | -2.072M |
| September 30, 2023 | -2.574M |
| June 30, 2023 | -3.424M |
| March 31, 2023 | -3.501M |
| December 31, 2022 | -3.028M |
| September 30, 2022 | -3.057M |
| June 30, 2022 | -2.497M |
| March 31, 2022 | -3.325M |
| December 31, 2021 | -3.461M |
| September 30, 2021 | -2.706M |
| June 30, 2021 | -3.487M |
| March 31, 2021 | -2.969M |
| December 31, 2020 | -2.989M |
| September 30, 2020 | -3.848M |
| June 30, 2020 | -3.573M |
| March 31, 2020 | -4.594M |
| December 31, 2019 | -3.501M |
| September 30, 2019 | -3.792M |
| June 30, 2019 | -3.75M |
| March 31, 2019 | -3.665M |
| December 31, 2018 | -3.642M |
| September 30, 2018 | -3.544M |
| June 30, 2018 | -3.217M |
| Date | Value |
|---|---|
| March 31, 2018 | -3.584M |
| December 31, 2017 | -3.486M |
| September 30, 2017 | -3.001M |
| June 30, 2017 | -2.945M |
| March 31, 2017 | -2.876M |
| December 31, 2016 | -15.59M |
| September 30, 2016 | 5.121M |
| June 30, 2016 | 0.075M |
| March 31, 2016 | 0.082M |
| December 31, 2015 | 0.09M |
| September 30, 2015 | 0.083M |
| June 30, 2015 | 0.073M |
| March 31, 2015 | 0.076M |
| December 31, 2014 | 0.061M |
| September 30, 2014 | 0.043M |
| June 30, 2014 | 0.066M |
| March 31, 2014 | 0.064M |
| December 31, 2013 | 0.005M |
| September 30, 2013 | 0.03M |
| June 30, 2013 | 0.009M |
| March 31, 2013 | -0.025M |
| December 31, 2012 | 0.038M |
| September 30, 2012 | 0.451M |
| June 30, 2012 | -0.129M |
| March 31, 2012 | -0.055M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-4.594M
Minimum
Mar 2020
-1.646M
Maximum
Jun 2024
-3.080M
Average
-3.057M
Median
Sep 2022
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -111.57M |
| Theriva Biologics Inc | -8.316M |
| Zevra Therapeutics Inc | -19.92M |
| PetIQ Inc | 15.32M |
| Instil Bio Inc | -14.92M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.003M |
| Total Expenses (Quarterly) | 1.652M |
| EPS Diluted (Quarterly) | -0.88 |
| Enterprise Value | 3.655M |
| Profit Margin (Quarterly) | -54.87K% |
| Earnings Yield | -224.2% |
| Normalized Earnings Yield | -224.17 |